AreƱo, Edna L.
HRN: 22-48-70 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
03/21/2023
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
03/21/2023
03/28/2023
IV
225 Mg
Q8H
T/c Sepsis
Waiting Final Action
Indication: Empiric Type of Infection: Bloodstream Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes